Status: Recruiting
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid tumors administered as a monotherapy and in combination with pembrolizumab.
Participants needed: 67
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: PharmAbcineUpdated: Dec 30, 2025Locations: 4
Eligibility criteria
The participant voluntarily signs an informed consent form (ICF) indicating they... [+21]
Has received treatment with a VISTA targeting agent. [+37]